This editorial refers to 'Ga i2 -mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart' by R.E. Waterson et al., this issue.
most powerful cardioprotective intervention yet discovered. As a consequence, an intense research effort has ensued in an attempt to elucidate the signalling mechanisms that mediate IPC so that practical therapies can be developed for patients who are predisposed to ischaemic disease. This work has resulted in identification of a number of pharmacological agents that mimic IPC, including adenosine, acetylcholine, opioids, calcitonin gene-related peptide, bradykinin, angiotensin II, and endothelin. 2 -4 Because each of these endogenously produced agonists serves as a ligand for Ga i protein-coupled receptors (GPCRs), there is growing interest in developing therapies that potentiate and/or sustain their activity in cardiovascular disease. Since it is difficult to predict when myocardial ischaemia will occur, this therapeutic approach may provide a novel away to target the treatment of the ischaemic heart on a temporal basis that allows for prophylactic management of individuals at risk for myocardial infarction.
GPCRs are the largest cell-surface receptor superfamily, with more than 800 of these proteins encoded in the human genome. 5, 6 Of these, more than 100 different GPCRs are expressed in the cardiovascular system. GPCRs respond to a wide variety of stimuli, including hormones, neurotransmitters, peptides, amino acids, nucleotides, lipids and fatty acid derivatives, and calcium ions, as well as light, chemical odorants, and taste molecules. The GPCRs transfer extracellular signals across the plasmalemma to intracellular effectors via heterotrimeric G proteins (a, b, and g).
The regulator of G protein signalling (RGS) proteins were discovered almost 15 years ago and are now recognized as important regulators of GPCR activity. 5, 6 They do so by acting as GTPase-activating proteins (GAPs) that enhance GTP hydrolysis, thereby terminating the G protein activation cycle. RGS proteins all share a 120-130 amino acid motif designated as the GAP (or RGS) domain that can increase the rate of Ga-mediated hydrolysis of GTP by 40 -2000-fold over basal levels. As a consequence, RGS proteins attenuate G protein signalling by accelerating G protein signal termination kinetics upon removal of the agonist. The GAP domain in RGS proteins can also physically block Ga-binding sites to downstream effectors as another mechanism for inhibiting GPCR signalling.
Waterson et al. 7 provide the first evidence that Ga i2 -mediated cardioprotection is attenuated by RGS proteins. Until this study, the lack of specific inhibitors for specific RGS proteins has made it difficult to address this question, an issue compounded by methodological problems caused by the tandem arrangement of many RGS protein genes on one chromosome, which make it difficult to create knockout mice lacking just one of the RGS proteins. However, Waterson et al. 7 capitalized on the recent development of genetically manipulated mice expressing a mutant Ga i2 (G184S) that is RGS insensitive. 8 This ingenious genomic knock-in approach permits enhanced Ga i2 signalling during I/R, since the G184S-Ga i2 mutant is unable to interact with RGS proteins, thereby limiting their negative regulation. This is a significant strength because the G184S knock-in model can be used to
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examine the effects of lifting constraints on Ga i2 -dependent signalling without altering receptor -effector coupling. In addition, because the RGS proteins have overlapping specificities and considerable functional redundancies, the role of individual RGS proteins can be difficult to dissect out in single knock-out models where only one RGS protein is deficient. On the other hand, the transgenic G184S-Ga i2 mutant protein limits all RGS proteins capable of interacting with Ga i2 from doing so. Using these mutant knock-in animals, Waterson et al. 7 showed that enhanced Ga i2 signalling induced by prevention of the negative regulation afforded by RGS proteins in the heart decreased myocardial infarct size, whereas the recovery of contractile function was significantly enhanced. These observations are consistent with earlier work conducted by DeGeorge et al. 9 who demonstrated that targeted inhibition of cardiac Gi signalling produced an increase in myocardial infarct size and reduced contractile performance. The findings of Waterson et al. 7 extend these observations by showing that elimination of the endogenous brake on Ga i2 signalling by mutating this G protein so that it unable to interact with RGS proteins is sufficient to produce substantial cardioprotection. These findings also imply that the release of molecules such as adenosine, bradykinin, calcitonin gene-related peptide, and opioids during ischaemia is insufficient to induce a protected phenotype in wild-type animals because the turnover kinetics for Ga i2 signalling are too rapid (owing to the ability for RGS proteins of promoting rapid termination of G-protein-mediated signals), but can become operative in the mutant mice as a consequence of increased potency. This conjecture also suggests the intriguing possibility that therapeutic strategies that remove constraints on Ga i -dependent signalling may represent a new avenue to reverse the effects of confounders (age, sex), co-morbidities (cardiovascular risk factors), and co-treatments (e.g. tachyphylaxis to preconditioning stimuli, nitrate intolerance) that reduce the effectiveness of IPC.
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The cardioprotective effects of enhanced Ga i2 signalling were greater in mice that were homozygous vs. heterozygous for the G184S-Ga i2 RGS-insensitive mutation, and the effects were prevented by treatment with inhibitors of mitochondrial and sarcolemmal ATP-sensitive potassium (K ATP ) channels. 7 However, the PI3K/Akt/ GSK-3-b and ERK/MEK signalling pathways, which have been shown to activate K ATP channels and protect against myocardial I/R injury in early phase preconditioning, 2, 11 do not appear to play a role in the protection afforded by enhanced Ga i2 activity. These results suggest that these signalling pathways may have already triggered K ATP channel activation in the mutant mice or that alternative signalling pathways are invoked to activate K ATP channels by the chronic enhancement of Ga i2 signalling in RGS-insensitive mutant mice. With regard to the latter, it is important to note that a number of RGS proteins inhibit the activity of other cardioprotective signalling molecules such as adenylyl cyclase.
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Based on the findings of the studies by Waterson et al., 7 one would expect that the infarct-sparing effects induced by treatment with agonists for Ga i2 -coupled receptors or by ischaemic preconditioning would be enhanced in the G184S-Ga i2 RGS-insensitive mutant mice. Although pharmacological preconditioning was not tested in these mice, ischaemic preconditioning with 3 bouts of 5 min ischaemia followed by 5 min of reperfusion reduced infarct size in wild-type mice, an infarct-sparing effect that was not magnified in mice either heterozygous or homozygous for the G184S mutation in Ga i2 . This finding was interpreted to indicate that expression of the G184S mutation in Ga i2 that renders it RGS-insensitive permits a maximal protective effect to occur in the face of low concentrations of endogenous cardioprotective agonists. While appealing in concept, this postulate could be readily addressed by conducting experiments in which the number of bouts of preconditioning ischaemia or concentration of G protein-coupled agonists were reduced to levels below the threshold for preconditioning in wild-type animals 11 and then testing whether these 'below threshold' stimuli would instigate preconditioning in the mutant mice. In summary, the novel observations of Waterson et al. 7 expand our understanding of cardioprotective mechanisms in myocardial I/R and open the door for development of new therapeutic strategies that target inhibition of specific RGS proteins as a means to enhance the potency of GPCR activation induced by ligands that activate Ga signalling. In addition, this study provides a sound basis for future studies examining the potential contribution to myocardial protection of the differing RGS proteins expressed in individual cell types. These questions will require application of reporter gene strategies combined with development tissue-and cell-specific conditional knockout mice for the RGS protein of interest. A likely outcome will be identification of new roles for RGS proteins that may not be apparent from studies conducted in global knock-out/knock-in mice, owing to potential compensatory changes in gene expression and or cell -cell communication among cardiac myocytes, endothelial and vascular smooth muscle cells, pericytes, fibroblasts, and immune cells, which differentially express the members of the RGS protein subfamilies. Indeed, Signarvic et al. 12 have recently demonstrated that platelet aggregation is enhanced in G184S-Ga i2 RGS-insensitive mutant mice as is platelet accumulation after vascular injury. Thus, lifting constraints on RGS/Ga i2 signalling may not always produce effects that benefit the ischaemic heart, perhaps especially in the setting of angioplasty.
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